Adage Capital Partners GP L.L.C. Purchases 32,591 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Adage Capital Partners GP L.L.C. grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 390,315 shares of the medical research company's stock after purchasing an additional 32,591 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 0.10% of Thermo Fisher Scientific worth $203,054,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Stonegate Investment Group LLC increased its stake in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock worth $3,531,000 after acquiring an additional 18 shares during the last quarter. Semus Wealth Partners LLC lifted its position in Thermo Fisher Scientific by 4.0% during the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after acquiring an additional 18 shares during the last quarter. Bangor Savings Bank lifted its holdings in shares of Thermo Fisher Scientific by 6.0% during the fourth quarter. Bangor Savings Bank now owns 334 shares of the medical research company's stock worth $174,000 after buying an additional 19 shares during the last quarter. Eagle Rock Investment Company LLC increased its position in Thermo Fisher Scientific by 0.3% during the fourth quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock worth $3,882,000 after acquiring an additional 19 shares during the period. Finally, KRS Capital Management LLC boosted its holdings in Thermo Fisher Scientific by 1.5% in the 4th quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock valued at $685,000 after purchasing an additional 20 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Scotiabank reduced their target price on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research note on Friday. UBS Group decreased their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday. Royal Bank of Canada cut their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday. Sanford C. Bernstein raised shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target on the stock in a report on Friday, January 10th. Finally, StockNews.com downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Friday. Five equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $616.95.

Insider Activity

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the transaction, the chief financial officer now owns 27,296 shares in the company, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the transaction, the executive vice president now owns 16,363 shares in the company, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $6.47 during trading on Monday, hitting $417.77. 1,267,017 shares of the stock were exchanged, compared to its average volume of 1,742,010. Thermo Fisher Scientific Inc. has a 1-year low of $409.85 and a 1-year high of $627.88. The stock has a market capitalization of $157.70 billion, a price-to-earnings ratio of 25.28, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86. The company has a fifty day moving average price of $487.28 and a 200-day moving average price of $526.70. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same period last year, the firm posted $5.11 earnings per share. The business's revenue was up .2% on a year-over-year basis. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's payout ratio is currently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.